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Abstract
Background: HIV infection and antiretroviral therapy (ART) may create unique risk factors for vitamin D
insufficiency, including alterations of vitamin D metabolism by ART. We prospectively compared demographic
and clinical parameters between vitamin D sufficient and insufficient HIV-infected (HIV+) adults, and assessed
changes in these parameters among insufficient participants following standardized vitamin D supplementation.
Methods: HIV+ adults (≥18 years old) with HIV-1 RNA <50 copies/mL on ART were enrolled. Vitamin D sufficiency
and insufficiency were defined as 25-hydroxyvitamin D (25(OH)D) ≥30 or <30 ng/mL, respectively. Insufficient
participants received open-label vitamin D3 50,000 IU twice weekly for 5 weeks, then 8000 IU twice weekly to
complete 24 weeks. The primary endpoint was success or failure to achieve 25(OH)D ≥30 ng/mL at week 24.
Results: Ninety-seven participants enrolled (34 vitamin D sufficient, 63 insufficient); 32 % female, 47 % non-White,
median age 46 years, ART duration 5 years, CD4+ T lymphocyte count (CD4) 673 cells/mm3. 25(OH)D repletion
was 83 % (95 % CI 71 %–90 %) successful. 25(OH)D levels correlated with both CD4 (r = 0.44, p = 0.01) and time
on protease inhibitor (r = −0.35, p = 0.01). After adjusting for age, sex, race, nadir CD4 and baseline 25(OH)D: 1)
current use of efavirenz exposure was associated with a 21.1 ng/mL higher week 24 25(OH)D level (p = 0.007), 2)
per year use of zidovudine was associated with 7.1 ng/mL reduction in week 24 serum 25(OH)D (p = 0.05) and 3)
every 1 ng/mL 25(OH)D increase was associated with a 3.3 cell/mm3 CD4 increase (p = 0.06).
Conclusion: Vitamin D3 supplementation was effective in repleting 25(OH)D levels after 24 weeks. Current efavirenz
use was positively associated with post-repletion 25(OH)D levels, while greater time on zidovudine was associated with
lower post-repletion 25(OH)D levels. The association between improved CD4 recovery and vitamin D repletion
suggests a potential benefit of vitamin D supplementation on immunologic recovery during HIV treatment.
Trial registration: This trial is registered at The Brazilian Clinical Trials Registry (U1111‐1165‐2537).
Introduction
Low serum 25-hydroxyvitamin D levels (25(OH)D
<30 ng/mL) are widely documented in both HIV-infected
persons and the general population [1–5]. While serum
25(OH)D levels have been associated with seasonal
variations in exposure to sunlight, high rates of vitamin D
insufficiency have also been documented in regions with
low latitude and year-round sun exposure, including
South America [6–10].
HIV infection may create unique risk factors for vitamin
D insufficiency such as chronic inflammation [11], and
both the protease inhibitor (PI) and non-nucleoside
reverse transcriptase inhibitor (NNRTI) classes of anti-
retroviral agents may enhance vitamin D metabolism via
modulation of the cytochrome P450 system and vitamin
D hydroxylation [1, 11–14]. Additionally, in HIV-infected
persons, vitamin D insufficiency has been associated with
lower CD4+ T lymphocyte counts [15, 16].* Correspondence: lara.coelho@ini.fiocruz.br1Instituto Nacional de Infectologia Evandro Chagas (INI), FIOCRUZ, Av Brasil
4365, Manguinhos, 21045-900 Rio de Janeiro, RJ, Brazil
Full list of author information is available at the end of the article
© 2015 Coelho et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
Coelho et al. Nutrition Journal  (2015) 14:81 
DOI 10.1186/s12937-015-0072-6
In the general population, the safety and efficacy of
vitamin D supplementation has been demonstrated at
a wide range of doses [17, 18]. In HIV-infected per-
sons, the safety of vitamin D supplementation has also
been described, but repletion success rates have been
less consistent [3, 19]. Given the associations of vitamin
D insufficiency with cardiovascular disease, insulin
resistance, progression to AIDS and increased mortality
[2, 15, 20–24], we designed an open-label trial of stan-
dardized vitamin D3 supplementation among HIV-
infected men and women on suppressive combination
antiretroviral therapy (ART) in Rio de Janeiro, Brazil.
Methods
Study design and study population
Participants were recruited from the adult HIV clinic at
the Evandro Chagas Clinical Research Institute (IPEC),
Oswaldo Cruz Foundation, which was established as a
referral center for HIV research and care in Rio de
Janeiro, Brazil in 1986. Eligible participants underwent
screening for vitamin D insufficiency as part of routine
clinical care between January 2011 and December 2013.
Inclusion criteria for this analysis included receipt of
ART (defined as two nucleoside reverse transcriptase in-
hibitors (NRTI) in combination with at least one PI or
one NNRTI) for at least six months prior to entry and
HIV-1 RNA <50 copies/mL at study entry. ART switches
in the six months prior to study enrollment were
allowed for tolerability but not virologic failure. Persons
receiving vitamin D supplementation >400 International
Units (IU, the amount in a standard multivitamin) at
screening were excluded from participation.
At screening, participants underwent serum 25(OH)D
measurement via chemiluminescence assay according to
the manufacturer instructions (Abbott, Chicago, IL).
Vitamin D sufficiency and insufficiency were defined as
25(OH)D levels ≥30 ng/mL and <30 ng/mL, respectively.
Insufficient participants were eligible to receive vitamin
D3 (cholecalciferol) supplementation and follow-up
every twelve weeks for at least 24 weeks, while those
with 25(OH)D ≥30 ng/mL served as a baseline control
group and did not require additional follow-up. For in-
sufficient subjects, vitamin D3 supplementation adher-
ence and tolerability were addressed at each follow-up
visit. Dual-energy X-ray absorptiometry (DXA) was of-
fered to all patients at baseline and was performed fol-
lowing manufacturer-recommended calibration and
maintenance procedures (Lunar Prodigy densitometer,
General Electric, Madison, WI). Lumbar spine and fem-
oral neck Z scores from DXA results were used to evalu-
ate the presence of osteopenia (Z-score between −1.0 and
−2.5) or osteoporosis (Z-score ≤ −2.5).
The study protocol was approved by the Evandro
Chagas Clinical Research Institute institutional review
board, and all participants provided written informed
consent prior to the initiation of study procedures. This
trial is registered at The Brazilian Clinical Trials
Registry (UTN: U1111‐1165‐2537).
Vitamin D supplementation
Participants with insufficient serum 25(OH)D levels were
prescribed a vitamin D3 supplementation regimen of
50,000 IU orally twice weekly for five weeks (repletion
phase) followed by 8000 IU twice a week for an additional
19 weeks (maintenance phase), a regimen similar to that
associated with high safety and repletion success [5, 25, 26]
(see Statistical Analysis, below) and within the guidelines
suggested by The Endocrine Society [27]. Vitamin D3 sup-
plements were provided to participants by the IPEC
research pharmacy in an emulsified 4000 IU D3 per drop
formulation (manufacturer Roche, Basel, Switzerland). All
participants received dosing and storage instructions.
Adherence was measured by self-report, as pill counts
could not be obtained using the emulsified D3 formulation.
Data collection
Socio-demographic and clinical information were ob-
tained from the clinical records of patients receiving
HIV care at IPEC, which is updated regularly using out-
patient and inpatient clinical documentation and labora-
tory testing results. ART use (drug, dates of use, and
dose) and other data were extracted from the clinical
record by trained abstractors, who recorded the infor-
mation onto standardized case report forms prior to
database entry.
Fasting glucose, lipid profile and glycosylated hemo-
globin, and CD4+ T lymphocyte counts and HIV-1 RNA
were assessed at baseline and week 24, according to local
standards.
Statistical analysis
The sample size calculation was based on the 85 % re-
pletion success rate of a similar cholecalciferol supple-
mentation regimen after twelve weeks in HIV-uninfected
adults with low bone mineral density [5]. For this study,
we predicted that HIV-infected persons might experi-
ence a less effective response to the intervention of
60 %. Based on this assumption, a minimum inclusion of
24 vitamin D insufficient participants provided 80 %
power (two-tailed, α=0.05) to reject the null hypothesis
that 60 % effectiveness is not statistically different from
the 85 % expected repletion success rate.
The primary endpoint was dichotomized success or
failure to achieve 25(OH)D ≥30 ng/mL after 24 weeks of
vitamin D3 supplementation. Secondary endpoints in-
cluded determination of associations between socio-
demographic and clinical features and both baseline and
week 24 25(OH)D levels, as well as an evaluation of the
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effects of vitamin D3 supplementation on metabolic and
immunological parameters.
Between-group comparisons for 1) baseline vitamin D
sufficiency vs. insufficiency and 2) failure vs. success of
repletion after 24 weeks were performed using the
Wilcoxon rank-sum test for continuous variables and
the chi-square or Fisher’s exact test for categorical vari-
ables. Linear regression models were used to quantify
the association of 25(OH)D levels with current ART ex-
posure and CD4+ T lymphocyte counts. The initial
multivariate models included all variables explored in
the bivariate analysis. Sex, age, race and nadir CD4+ T
lymphocyte count were maintained in the final multi-
variate models irrespective of p-values due to prior
reports of associations with 25(OH)D levels. In addition,
current antiretroviral drugs/classes were initially in-
cluded and removed by backwards elimination until a
p-value of < 0.05 was present for all ART variables.
Results
Study population
One hundred participants were screened and 99 en-
rolled. Of those 99, one participant withdrew consent
and one was lost to follow-up, leaving 97 evaluable
participants. Sixty-three participants had vitamin D
insufficiency and initiated supplementation, whereas
34 participants were classified as vitamin D sufficient
at baseline and were included as controls (Fig. 1).
Overall, the median age of the study population was
45 years, 68 % were men, median baseline CD4+ T
lymphocyte count was 673 cells/mm3, median time on
ART was 5 years and the most common ART agents in
current use were tenofovir (71 %) and efavirenz (70 %)
(Table 1).
Baseline differences by serum 25(OH)D level
At baseline, vitamin D sufficient and insufficient partici-
pants differed mainly by serum 25(OH)D level (Table 1).
Although absolute current and nadir CD4+ T lymphocyte
counts did not differ significantly between groups, the
proportion of participants with a CD4+ T lymphocyte
nadir <50 cells/mm3 was 26 % among insufficient partici-
pants vs. 6 % among sufficient participants (p = 0.04).
Regarding ART use, efavirenz use was more frequent
among insufficient participants (73 % vs. 65 %, p = 0.54),
who also had a longer exposure to this drug (p = 0.10).
The proportion of patients on zidovudine was also
higher in the insufficient group (35 % vs. 24 %, p = 0.35),
while tenofovir and PI use were more common in the
sufficient group (tenofovir: 77 % vs. 68 %, p = 0.54; PI:
35 % vs. 24 %, p = 0.33). Regarding body mass index,
overall there was no significant difference between the
groups, although obesity was more prevalent in the in-
sufficient group (17 % vs. 0 %, p = 0.08) (Table 1).
Baseline associations between 25(OH)D level and clinical
parameters
Associations between current antiretroviral drug use
and baseline 25(OH)D levels were evaluated using lin-
ear regression. In unadjusted models, per year PI ex-
posure was associated with 1.69 ng/mL lower baseline
25(OH)D level (p = 0.03). Negative but non-significant
associations were also observed for per year use of zi-
dovudine, efavirenz and tenofovir. After controlling for
sex, age, race and nadir CD4+ T lymphocyte count, per
year exposure to any of the included ART drugs/classes
was associated with lower baseline 25(OH)D levels, but
those associations were non significant. Current PI use
was associated with a 6.9 ng/mL higher baseline
25(OH)D level (p = 0.02) (Table 2A).
Baseline associations between DXA results and
demographic and clinical parameters
In the subset of participants with DXA results (n = 54),
the prevalence of bone disease was high, with 68 % of
vitamin D sufficient and 71 % of vitamin D insufficient
participants having osteopenia or osteoporosis. While
not statistically significant, the prevalence of osteopor-
osis was numerically greater in the vitamin D insufficient
group (26 % vs. 5 %, p = 0.08) (Table 1).
25(OH)D levels did not differ between participants with
any bone disease (osteoporosis or osteopenia) and those
with normal Z score range (24 vs. 27 ng/mL respectively,
p = 0.90, Additional file 1: Table S1). Participants with
bone disease were more likely to be female (34 % vs. 19 %,
p = 0.34), non-White (58 % vs. 38 %, p = 0.28), have a nadir
CD4+ T lymphocyte count <50 cells/mm3 (25 % vs. 0 %,
p = 0.04) and use efavirenz (79 % vs. 63 %, p = 0.31).
Neither bivariate nor multivariate modeling revealed
Fig. 1 Study flow-chart: screening and enrollment of study participants
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Table 1 Baseline demographic and clinical characteristics
Sufficient group Insufficient group Total P-value
n = 34 n = 63 n = 97
25(OH)D (ng/mL) 38 (34, 43) 21 (16, 24) 24 (18, 35) <0.001
Male sex 74 % (25) 65 % (41) 68 % (66) 0.53
Age (years) 45 (38, 50) 47 (38, 53) 45 (38, 52) 0.87
White race/ethnicity 50 % (17) 54 % (34) 53 % (51) 0.87
Nadir CD4+ T lymphocyte (cells/mm3) 185 (97, 230) 143 (49, 242) 170 (71, 236) 0.39
≥ 350 3 % (1) 3 % (2) 3 % (3)
200–349 38 % (12) 34 % (21) 36 % (33)
50–199 53 % (17) 36 % (22) 42 % (39)
< 50 6 % (2) 26 % (16) 19 % (18)
Baseline CD4+ T lymphocyte (cells/mm3) 650 (437, 754) 688 (499, 792) 673 (465, 775) 0.39
≥ 500 66 % (19) 74 % (43) 72 % (62)
350–499 24 % (7) 16 % (9) 18 % (16)
< 350 10 % (3) 10 % (6) 10 % (9)
Time on ART (years) 5 (4, 5) 5 (5, 6) 5 (4, 6) 0.40
Time on TDF (years) 3 (1, 4) 3 (0, 5) 3 (1, 5) 0.42
Time on AZT (years) 0 (0, 4) 0 (0, 5) 0 (0, 5) 4(1.3,4.9) 0.06
Time on EFV (years) 3 (0, 5) 4 (2, 5) 4 (1, 5) 0.10
Time on PI (years) 2 (0, 5) 0 (0, 2) 0 (0, 5) 0.10
Current TDF use 77 % (26) 68 % (43) 71 % (69) 0.54
Current AZT use 24 % (8) 35 % (22) 31 % (30) 0.35
Current EFV use 65 % (22) 73 % (46) 70 % (68) 0.54
Current PI use 35 % (12) 24 % (15) 28 % (27) 0.33
DXA classificationa 0.17
Normal 32 % (6) 29 % (10) 30 % (16)
Osteopenia 63 % (12) 46 % (16) 52 % (28)
Osteoporosis 5 % (1) 26 % (9) 18 % (10)
Any bone diseaseb 68 % (13) 71 % (25) 70 % (38) 0.10
BMIa (kg/m2) 25 (23, 27) 25 (24, 28) 25 (23, 27) 0.46
< 18.5 5 % (1) 0 (0) 2 % (1)
18.5–24.9 47 % (9) 51 % (18) 50 % (27)
25.0–29.9 47 % (9) 31 % (11) 11 % (6)
≥ 30.0 0 (0) 17 % (6) 37 % (20)
C-reactive protein (mg/dL) 0.2 (0.3, 0.9) 0.3 (0.2, 0.6) 0.3 (0.2, 0.6) 0.56
Glucose (mg/dL) 89 (81, 95) 88 (81, 93) 88 (81, 93) 0.73
HbA1c (%) 5.5 (5.3, 5.7) 5.5 (5.3, 5.7) 5.5 (5.3, 5.7) 0.84
Triglycerides (mg/dL) 108 (76, 181) 121 (86, 185) 120 (80, 184) 0.55
Total cholesterol (mg/dL) 195 (171, 223) 196 (173, 217) 196 (172, 221) 0.82
HDL (mg/dL) 45 (37, 51) 47 (39, 58) 47 (39, 58) 0.60
LDL (mg/dL) 117 (93, 140) 120 (92, 145) 118 (92, 143) 0.89
Median (interquartile range) or percent (n) presented
25(OH)D 25-hydroxyvitamin D, TDF tenofovir, AZT zidovudine, EFV efavirenz, PI protease inhibitor, DXA dual-energy X-ray absorptiometry, BMI body mass index,
HbA1c glycated hemoglobin
aData available for 54 patients (19 in sufficiency group, 35 in insufficiency group)
bAny bone disease aggregates osteoporosis and osteopenia
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significant associations between demographic and clinical
features and the presence of bone disease (data not
shown).
Vitamin D repletion effectiveness
Twenty-four weeks of vitamin D3 supplementation was
successful in achieving serum 25(OH)D levels ≥30 ng/mL
in 83 % (n = 52/63, 95 % CI 71–90 %) of participants. Par-
ticipants were classified at week 24 as either repletion re-
sponders (25(OH)D ≥30 ng/mL) or non-responders
(25(OH)D persistently <30 ng/mL), with a median post-
repletion serum 25(OH)D level of 47 ng/mL among re-
sponders vs. 26 ng/mL among non-responders (Table 3).
Overall, non-responders were somewhat younger
(median 42 vs. 48 years, p = 0.27), had lower nadir and
baseline CD4+ T lymphocyte counts (baseline median
540 vs. 689 cells/mm3, p = 0.69), and were more likely
to use tenofovir (100 % vs. 65 %, p = 0.09) and PIs than
responders (38 % vs. 19 %, p = 0.35). Non-responders
also had a significantly lower proportion of current
zidovudine use (0 % vs. 39 %, p = 0.04) and higher post-
repletion fasting glucose levels (91 vs. 82 mg/dL, p = 0.02)
(Table 3).
Associations between successful vitamin D repletion and
clinical parameters
Among responders, bivariate analysis demonstrated a
17.9 ng/mL higher week 24 serum 25(OH)D level among
current efavirenz users (p = 0.01), whereas current PI use
was associated with a 16.2 ng/mL lower week 24 serum
25(OH) D level (p = 0.03). After adjusting for age, sex,
race, nadir CD4+ T lymphocyte count and baseline
25(OH)D, current efavirenz use was associated with a
21.1 ng/mL increase in week 24 serum 25(OH)D level
(p = 0.007, Table 2B).
For the effect of duration of ART exposure, after
adjusting for sex, age, nadir CD4+ T lymphocyte count
and baseline 25(OH)D, per year use of zidovudine was
associated with a 7.1 ng/mL lower week 24 serum
25(OH)D (p = 0.05). For the other ART drugs/classes,
per year exposure was associated with lower week 24
serum 25(OH)D levels (tenofovir = −1.55, p = 0.33; efa-
virenz = −1.36, p = 0.60; PI = −0.17, p = 0.96), although
these did not achieve statistical significance.
Among participants who received vitamin D supple-
mentation, there was no significant difference between
median baseline CD4+ T lymphocyte count for re-
sponders and non-responders (689 vs. 540 cells/mm3,
p = 0.69). Compared to baseline, week 24 CD4+ T
lymphocyte counts increased in both groups (median
at week 24 712 cells/mm3 for responders vs. 656 cells/
mm3 for non-responders) (Table 3). Additionally, a
significant positive correlation was observed between
24-week changes in CD4+ T lymphocyte counts and
25(OH)D levels among responders (r = 0.44, p = 0.01).
After adjusting for age, sex, race and nadir CD4+ T
lymphocyte count, each 1.0 ng/mL increase in
25(OH)D during repletion therapy was associated with
a 3.3 cell/mm3 increase in CD4+ T lymphocyte count
(p = 0.06, Table 4).
Discussion
Despite high rates of reported vitamin D insufficiency in
treated HIV infection, little has been published on the
relationships between ART use and success or failure of
vitamin D supplementation. In this cohort of HIV-
infected adults on suppressive ART, we demonstrated
Table 2 Linear models for 25(OH)D levels (ng/mL) at baseline
and at week 24 for responders (n = 52)
Part A.
Baseline (n = 97)
Unadjusted model Adjusted model
Beta (95 % CI) Beta (95 % CI)
Female sex −1.08 (−7.27, 5.12) −5.57 (−11.40, 0.26)
Age (years) −0.16 (−0.44, 0.11) −0.20 (−0.46, 0.05)
Non-white race/
ethnicity
2.48 (−3.29, 8.25) 2.64 (−2.78, 8.06)
Nadir CD4+ T
lymphocyte (per 100
cells/mm3)
0.57 (−2.04, 3.18) 1.17 (−1.42, 3.75)
Current use of TDF 5.84 (−0.43, 12.12)
Current use of AZT −5.27 (−11.44, 0.89)
Current use of EFV −1.65 (−7.96, 4.66)
Current use of PI −2.85 (−3.55, 9.30) 6.93 (0.96, 12.90)
Part B.
Week 24a (n = 52)
Unadjusted model Adjusted model
Beta (95 % CI) Beta (95 % CI)
Female sex −4.08 (−16.61, 8.46) −0.96 (−14.20, 12.27)
Age (years) −0.22 (−0.78, 0.33) 0.21 (−0.38, 0.79)
Non-white race/
ethnicity
−5.02 (−16.95, 6.91) −5.53 (−17.82, 6.77)
Nadir CD4+ T
lymphocyte (per 100
cells/mm3)
1.94 (−3.44, 7.31) 3.29 (−1.96, 8.54)
Baseline 25(OH)D 1.17 (0.25, 2.09) 1.27 (0.24, 2.30)
Current use of TDF −10.24 (−22.50, 2.02)
Current use of AZT 7.44 (−4.70, 19.57)
Current use of EFV 17.88 (4.08, 31.68) 21.09 (6.41, 35.78)
Current use of PI −16.15 (−31.10, −2.13)
25(OH)D 25-hydroxyvitamin D, TDF tenofovir, AZT zidovudine, EFV efavirenz, PI
protease inhibitor
aFor those who underwent vitamin D supplementation and achieved 25(OH)D
levels > 30 ng/mL at week 24
Bold font implies statistically significant results assuming a 5%
significance threshold
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high rates of vitamin D insufficiency but success of
vitamin D repletion with a standardized regimen similar
to repletion success rates reported among HIV-uninfected
persons [5].
25(OH)D levels have recently been shown to decline
in the 24 weeks following initiation of efavirenz with ei-
ther lamivudine/zidovudine or emtricitabine/tenofovir,
but to stabilize thereafter [28]. With an average time on
ART of five years, we were not able to assess changes in
25(OH)D levels related to ART initiation; however,
vitamin D insufficiency has also been associated with
current efavirenz and nevirapine use irrespective of
length of treatment [29–33]. While efavirenz use was
more common among participants with baseline vitamin D
Table 3 Demographic and clinical characteristics at week 24 among participants who underwent vitamin D3 supplementation
WNon-responders Responders P-value
(25(OH)D < 30 ng/mL) (25(OH)D ≥30 ng/mL)
(n = 8) (n = 52)
25(OH)D (ng/mL)a 26 (25, 27) 47 (40, 65) <0.001
Male sex 63 % (5) 65 % (34) 1.00
Age (years) 42 (36, 48) 48 (39, 54) 0.27
White race/ethnicity 63 % (5) 54 % (28) 0.72
Baseline CD4+ T lymphocyte (cells/mm3) 540 (509, 758) 689 (527, 833) 0.69
≥500 71 % (5) 77 % (37)
350–499 14 % (1) 17 % (8)
<350 14 % (1) 6 % (3)
Week 24 CD4+ T lymphocyte (cells/mm3) 656 (600, 891) 712 (460, 853) 0.50
≥500 100 % (5) 67 % (22)
350–499 0 (0) 21 % (7)
<350 0 (0) 12 % (4)
Time on cART (years) 5 (4, 8) 5 (5, 6) 0.96
Time on TDF (years) 4 (3, 5) 3 (0, 5) 0.30
Time on AZT (years) 0 (0, 2) 1 (0, 5) 0.50
Time on EFV (years) 2 (2, 4) 4 (3, 5) 0.31
Time on PI (years) 1 (0, 6) 0 (0, 2) 0.36
Current TDF use 100 % (8) 65 % (34) 0.09
Current AZT use 0 % (0) 39 % (20) 0.04
Current EFV use 50 % (4) 79 % (41) 0.10
Current PI use 38 % (3) 19 % (10) 0.35
Baseline BMIb (kg/m2) 23 (23, 24) 25 (24, 28) 0.23
<18.5 0 % (0) 0 % (0)
18.5–24.9 100 % (3) 48 % (15)
25.0–29.9 0 % (0) 32 % (10)
≥30.0 0 % (0) 19 % (6)
C-reactive protein (mg/dL) 0.3 (0.2, 0.4) 0.3 (0.2, 0.9) 0.36
Glucose (mg/dL) 82 (80, 89) 91 (87, 103) 0.02
HbA1c (%) 5.5 (5.5, 5.8) 5.5 (5.2, 5.8) 0.62
Triglycerides (mg/dL) 111 (105, 128) 150 (107, 201) 0.12
Total cholesterol (mg/dL) 187 (166, 200) 198 (173, 225) 0.41
HDL (mg/dL) 51 (48, 53) 47 (40, 60) 0.52
LDL (mg/dL) 111 (94, 124) 110 (93, 133) 0.87
Median (interquartile range) or percent (n) presented
25(OH)D 25-hydroxyvitamin D, TDF tenofovir, AZT zidovudine, EFV efavirenz, PI protease inhibitors, BMI body mass index, HbA1c glycated hemoglobin
aNo available 25(OH)D at week 24 for 3 participants
bData available for 54 patients (19 in sufficiency group, 35 in deficiency group)
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insufficiency in our cohort, we observed a positive associ-
ation between duration of efavirenz use and success of vita-
min D repletion that is consistent with other studies that
did not show an inhibitory effect of efavirenz on success of
vitamin D repletion [34]. While elucidating a mechanism
for this finding is beyond the scope of this study, it is pos-
sible that complex interactions between vitamin D, efavir-
enz and the cytochrome P450 system [14, 35] allow for
enhanced efficacy of supplementation.
Despite potentially enhancing vitamin D metabolism, PI
therapy has not consistently been associated with vitamin
D insufficiency, and PI monotherapy has been associated
with decreased risk of vitamin D insufficiency [36]. At
baseline, we observed similar rates of PI use among partici-
pants with sufficient and insufficient 25(OH)D levels.
Additionally, while we observed a strong correlation be-
tween PI use and success of vitamin D repletion, PI use was
not associated with success or failure of vitamin D repletion
in this analysis after adjusting for confounding factors.
In our analysis, baseline rates of bone disease (osteopenia
or osteoporosis) did not vary by 25(OH)D level. In an indi-
genous, adult Brazilian population, lower 25(OH)D levels
also did not predict decreased bone mineral density [37],
but lower high-density lipoprotein cholesterol were associ-
ated with lower 25(OH)D levels. Given the known interac-
tions of high-density lipoprotein with osteoclasts and
osteoblasts [38], we assessed this relationship in our cohort,
but did not find an association between high-density
lipoprotein cholesterol and bone mineral density in the sub-
set of participants who underwent DXA scanning (data not
shown).
Lastly, we observed a positive association between
changes in 25(OH)D levels and CD4+ T lymphocyte
counts, a finding that has been previously reported
[16, 39–41], although not with consistent results [42–44].
Vitamin D supplementation has also been associated with
a decreased Th17-to-Tregulatory lymphocyte ratio [43],
decreased expression of CD38+ and Ki67+ on memory
CD8+ T lymphocytes [45], increased regulatory T lympho-
cyte numbers [43, 46], enhanced Th2-dependent cytokine
expression and decreased Th1-dependent cytokine levels
[47], which may help to limit ongoing immune activation
in settings such as treated HIV infection. As such, larger
studies designed to look at the effects of vitamin D supple-
mentation on T lymphocyte recovery and immune activa-
tion are warranted.
This study has several limitations. First, the sample
size was based on the primary objective (to assess the
effectiveness of a standardized vitamin D supplementa-
tion regimen), and was likely too small to fully evaluate
relationships between changes in 25(OH)D levels and
specific clinical and demographic factors, including spe-
cific ART agents and metabolic parameters. Second, the
metabolic and immunological parameters we evaluated
were restricted to those routinely performed in accord-
ance with Brazilian guidelines. Third, DXA results were
available for only a subset of consenting participants,
and therefore do not represent a random sample of our
larger cohort. Similarly, the findings presented here
cannot be generalized to the entire IPEC cohort or Bra-
zilian HIV-infected population for many reasons, in-
cluding differences among individuals who were
enrolled in the cohort over time, possible cohort effects
and the non-probabilistic characteristics of the sample
included in this study. Finally, we could not stringently
assess adherence to vitamin D supplementation due to
supplement formulation.
In conclusion, standardized vitamin D3 supplemen-
tation was effective in repleting 25(OH)D levels after
24 weeks. Time on efavirenz was positively associated
with post-repletion 25(OH)D levels, whereas no sig-
nificant associations were observed for other antire-
troviral agents. The strong correlation and association
between increases in 25(OH)D levels and CD4+ T
lymphocyte counts supports a benefit of vitamin D
supplementation on immunologic recovery, which is
particularly relevant to the HIV-infected population.
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Table 4 Linear models for 24-week CD4+ T lymphocyte count
change among participants that achieved vitamin D sufficiency
(n = 31)
Unadjusted model (CI) Adjusted model (CI)
Female sex −13.02 (−152.29, 126.25) −57.81 (−186.60, 70.99)
Age (years) 8.82 (3.04, 14.60) 9.42 (3.67, 15.48)
Non-white race/
ethnicity
−38.46 (−175.34, 98.42) −46.00 (−177.50, 85.50)
Nadir CD4+
T lymphocyte
(per 100 cells/mm3)
0.32 (−71.24, 71.88) −8.04 (−73.65, 57.56)
Change in 25(OH)D
levels (ng/ml)
4.39 (1.01, 7.76) 3.25 (−0.05, 6.55)
25(OH)D 25-hydroxyvitamin D
Bold font implies statistically significant results assuming a 5%
significance threshold
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